CORONA Remedies Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 19, 2026
- Posted by: Kunal Singla
- Category: News
The CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from the current market price of Rs 1,833 (NSE: CORONA). With Q4 FY26 results released in 2026 and Pharmaceutical Formulations and APIs tailwinds in focus, the Rs 2,200 price objective is supported by the FY27 earnings recovery thesis.
CORONA Remedies (NSE: CORONA) is a Pharmaceutical Formulations and APIs company trading at Rs 1,833 with a market capitalisation of Rs 1,833 crore. Analysts have set the CORONA Remedies share price target at Rs 2,200 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
CORONA Remedies Share Price Target 2026: Key Takeaways
- CORONA Remedies share price target 2026: Rs 2,200 (20% upside from CMP Rs 1,833)
- Bull case: Rs 2,650 | Bear case: Rs 1,450
- Ticker: CORONA | Sector: Pharmaceutical Formulations and APIs | MCap: Rs 1,833 crore
- 52W range: Rs 1,270 to Rs 3,007 | PE: 25x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
CORONA Remedies Company Overview
CORONA Remedies (NSE: CORONA) is an Ahmedabad-based pharmaceutical company manufacturing oncology, hormonal, and specialty formulations, along with APIs for regulated export markets, with a growing branded prescription portfolio. At CMP Rs 1,833 against a 52 week range of Rs 1,270 to Rs 3,007, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,833 crore with trailing PE of 25x. Compared to peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals, CORONA Remedies is positioned as a potential re-rating candidate toward the Rs 2,200 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | CORONA |
| Sector | Pharmaceutical Formulations and APIs |
| CMP (2026) | Rs 1,833 |
| 52 Week High | Rs 3,007 |
| 52 Week Low | Rs 1,270 |
| Market Cap | Rs 1,833 crore |
| Trailing PE | 25x |
| 12-Month Analyst Target | Rs 2,200 |
| Bull Case Target | Rs 2,650 |
| Bear Case Target | Rs 1,450 |
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Why Is the CORONA Remedies Share Price Target Set at Rs 2,200 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The CORONA Remedies share price target of Rs 2,200 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 2,200 price objective represents the base case with FY27 execution as the key variable.
Structural Sector Tailwinds in Pharmaceutical Formulations and APIs
The Pharmaceutical Formulations and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. CORONA Remedies’s position among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 2,650 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve CORONA Remedies’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 2,200 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for CORONA Remedies’s Pharmaceutical Formulations and APIs operations, improving the probability of achieving the Rs 2,200 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, CORONA Remedies is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 2,650 bull case over the medium term.
CORONA Remedies Share Price Targets: Short Term, 12 Month, and Long Term
Short Term CORONA Remedies Share Price Target
Near-term support for CORONA Remedies is anchored close to the 52 week low of Rs 1,270. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.
12-Month CORONA Remedies Share Price Target 2026
The 12-month CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from CMP Rs 1,833. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker CORONA.
Long Term CORONA Remedies Share Price Target: FY27 to FY28
The long term CORONA Remedies share price target for FY27 to FY28 is Rs 2,650 in the bull case, requiring full earnings delivery, re-rating among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for CORONA Remedies in 2026
Bull Case CORONA Remedies Share Price Target: Rs 2,650
The bull case CORONA Remedies share price target of Rs 2,650 materialises when FY27 earnings beat analyst estimates, Pharmaceutical Formulations and APIs tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 1,833, this represents approximately 45 percent potential upside.
Bear Case CORONA Remedies Share Price Target: Rs 1,450
The bear case CORONA Remedies share price target of Rs 1,450 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 1,270.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 2,650 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 2,200 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 1,450 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the CORONA Remedies 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the CORONA Remedies share price target of Rs 2,200, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 2,200 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Pharmaceutical Formulations and APIs Peers
Intensifying competition from peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals could compress CORONA Remedies’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 2,200 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in CORONA Remedies
Check the Univest Screener for live data
Before considering any investment based on the CORONA Remedies share price target of Rs 2,200, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical Formulations and APIs sector demand.
Open a Demat account with a SEBI registered stockbroker to trade CORONA Remedies (NSE: CORONA) with regulatory protection. Study the competitive landscape among peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals before executing any position.
Plan your entry using the 52 week low of Rs 1,270 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 2,200 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track CORONA Remedies’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on CORONA Remedies Share Price Target 2026
What is the CORONA Remedies share price target for 2026?
Ans. The CORONA Remedies share price target 2026 is Rs 2,200, implying approximately 20 percent upside from CMP Rs 1,833. Bull case is Rs 2,650, bear case is Rs 1,450.
What was the CORONA Remedies share price target for 2025?
Ans. The 2025 price objective for CORONA Remedies was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 2,200, reflecting FY27 growth potential from CMP Rs 1,833.
Is CORONA Remedies a good investment at Rs 1,833?
Ans. At Rs 1,833, CORONA Remedies offers potential upside toward Rs 2,200 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.
What are the key risks to the CORONA Remedies share price target 2026?
Ans. Key risks to the CORONA Remedies share price target of Rs 2,200 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical Formulations and APIs. Monitoring quarterly results is essential.
What is the 52 week high and low of CORONA Remedies?
Ans. The 52 week high of CORONA Remedies is Rs 3,007 and the 52 week low is Rs 1,270. At CMP Rs 1,833, the stock is below its 52 week high and offers potential upside toward the Rs 2,200 price objective.
What are the main growth catalysts for CORONA Remedies in 2026?
Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical Formulations and APIs sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does CORONA Remedies compare to its peers?
Ans. CORONA Remedies operates in Pharmaceutical Formulations and APIs alongside peers in specialty pharma like Sun Pharma and Alembic Pharmaceuticals. At CMP Rs 1,833 with MCap Rs 1,833 crore, it is a potential re-rating candidate toward the CORONA Remedies share price target of Rs 2,200 on FY27 delivery.
What is the CORONA Remedies share price target for 2027?
Ans. The long-term CORONA Remedies share price target for FY27 to FY28 is Rs 2,650 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
